Moderna's 177% Squeeze Is a Warning. These 3 Stocks Could Be Next

JUST IN: Moderna just did something that doesn't happen in biotech. Not usually. Not with a straight face.

Shares exploded 177% Wednesday after its personalized mRNA cancer vaccine with Merck nailed a Phase 3 melanoma trial. That's roughly $30 billion in market value added in a single session. Heavy short covering did the heavy lifting. Shorts got caught on the wrong side of a real medical breakthrough and paid for it.

Then came the whiplash. Moderna fell 23.6% the next day. Because that's how meme stocks work. The rally brings in momentum traders. Momentum traders leave. And the stock settles somewhere between the hype and the science.

Here's the thing. That wild swing wasn't random. It was the result of a specific setup: big short interest, a hard catalyst, and retail traders who smell blood. And according to the report, three American stocks are sitting on the same setup right now.

That should scare you a little. It also should make you pay attention.

The market's verdict: short squeezes are momentum events, not value events. The companies with this setup don't need to be good. They need to be early. And these three are in that position.

So what's the play? Don't chase the green candle. Watch for the initial move and wait for the first pullback. That's where the actual trade lives. And honestly, that's where most people miss it.

Traders are watching closely. Because the formula is straightforward. Find a stock with heavy short interest. Wait for a catalyst that forces bears to cover. Then let the buying feed on itself. Moderna just showed how violent that can be.

But there's a catch. That 23.6% drop proves the move cuts both ways. If you're late, you're the exit liquidity. The question is whether these three will follow the full Moderna path or skip straight to the crash.

This changes things. The biotech playbook just got a new chapter. And the next three names might already be in the first paragraph.